Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
Ageno W , Lopes RD , Yee MK , Hernandez A , Hull R , Goldhaber SZ , Gibson CM , Cohen AT
Journal of thrombosis and haemostasis : JTH
Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk-benefit of betrixaban in patients aged ≥80 years enrolled in the APEX trial.
Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved